VP
venBio Partners Portfolio holdings
AUM
$115M
This Quarter Return
-11.09%
1 Year Return
-33.99%
3 Year Return
+221.07%
5 Year Return
+224.54%
10 Year Return
–
AUM
$171M
AUM Growth
+$171M
(-12%)
Cap. Flow
+$1.5M
Cap. Flow
% of AUM
0.88%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
–
Reduced
3
Closed
–
Top Buys
| 1 |
Lyell Immunopharma
LYEL
|
$4.55M |
Top Sells
| 1 |
Harmony Biosciences
HRMY
|
$2.59M |
| 2 |
ALMS
Alumis Inc. Common Stock
ALMS
|
$304K |
| 3 |
SLRN
ACELYRIN
SLRN
|
$145K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Pharvaris
PHVS
$1.39B
| $82.2M | 48.17% | 4,289,304 | – | – |
|
|
ALMS
2
Alumis Inc. Common Stock
ALMS
$479M
| $21.9M | 12.83% | 2,787,398 -38,650 | -1% | -$304K |
|
|
3
Harmony Biosciences
HRMY
$2.12B
| $18.6M | 10.87% | 539,194 -75,400 | -12% | -$2.59M |
|
4
ALX Oncology
ALXO
$62.7M
| $16.2M | 9.49% | 9,699,925 | – | – |
|
|
ARTV
5
Artiva Biotherapeutics, Inc. Common Stock
ARTV
$76.7M
| $15.3M | 8.98% | 1,519,971 | – | – |
|
|
SLRN
6
DELISTED
ACELYRIN
SLRN
| $12M | 7% | 3,806,410 -46,060 | -1% | -$145K |
|
|
7
Lyell Immunopharma
LYEL
$213M
| $4.55M | 2.66% | +7,102,190 | New | +$4.55M |
|